Abdeta Abera, Beyene Degefu, Negeri Abebe Aseffa
National Clinical Bacteriology and Mycology Reference Laboratory, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Infect Drug Resist. 2023 Sep 13;16:6155-6166. doi: 10.2147/IDR.S429687. eCollection 2023.
The study aimed to investigate the antimicrobial resistance patterns of and species isolated from clinical specimens over a period of five years, including resistance to methicillin and vancomycin.
Bacterial identification and antimicrobial susceptibility testing reports from 2017 to 2021 at the Ethiopian Public Health Institute were used for this retrospective study. The organisms were identified using either BD Phoenix M50, Vitek 2 compact, or conventional biochemical methods, whichever was available at the time of testing. The antimicrobial susceptibility profiles of the isolates were determined using either Kirby-Bauer disc diffusion, BD phoenix M50, or Vitek 2 compact. WHONET software was used to analyze the antimicrobial resistance patterns of both organisms. The p-values of ≤0.05 were considered statistically significant.
During the study period, a total of 315 and 92 species were isolated. Out of 315 isolates, 27% and 5.1% were methicillin and vancomycin resistant, respectively. showed very high resistance to Penicillin G (86.7%). Out of 92 species recovered, 8.7% were vancomycin-resistant. species showed very high resistance to Penicillin G (71.4%) and tetracyclines (83.3%). Methicillin-resistant shows 100% resistance to penicillin followed by ciprofloxacin (50%), erythromycin (45.6%), and tetracycline (44.2%) and lower resistance to vancomycin (18.8%). All vancomycin-resistant isolates of both organisms were fully resistant (100%) to all antibiotics tested, except for linezolid and daptomycin, to which they were susceptible.
This study found a high prevalence of methicillin and vancomycin-resistant and vancomycin-resistant species between 2017 and 2021. However, there were no statistically significant changes in the prevalence of these organisms during the study period. This suggests that larger and more representative nationwide data is needed to show trends of these pathogens.
本研究旨在调查五年期间从临床标本中分离出的[具体细菌名称1]和[具体细菌名称2]的抗菌药物耐药模式，包括对甲氧西林和万古霉素的耐药情况。
本回顾性研究使用了埃塞俄比亚公共卫生研究所2017年至2021年的细菌鉴定和抗菌药物敏感性测试报告。使用BD Phoenix M50、Vitek 2 compact或传统生化方法（测试时可用的任何方法）对微生物进行鉴定。使用Kirby-Bauer纸片扩散法、BD phoenix M50或Vitek 2 compact确定分离株的抗菌药物敏感性谱。使用WHONET软件分析这两种微生物的抗菌药物耐药模式。p值≤0.05被认为具有统计学意义。
在研究期间，共分离出315株[具体细菌名称1]和92株[具体细菌名称2]。在315株[具体细菌名称1]分离株中，分别有27%和5.1%对甲氧西林和万古霉素耐药。[具体细菌名称1]对青霉素G的耐药率非常高（86.7%）。在92株分离出的[具体细菌名称2]中，8.7%对万古霉素耐药。[具体细菌名称2]对青霉素G（71.4%）和四环素（83.3%）的耐药率非常高。耐甲氧西林的[具体细菌名称1]对青霉素的耐药率为100%，其次是环丙沙星（50%）、红霉素（45.6%）和四环素（44.2%），对万古霉素的耐药率较低（18.8%）。两种微生物的所有耐万古霉素分离株对所有测试抗生素均完全耐药（100%），但对利奈唑胺和达托霉素敏感。
本研究发现2017年至2021年间耐甲氧西林和耐万古霉素的[具体细菌名称1]以及耐万古霉素的[具体细菌名称2]的患病率较高。然而，在研究期间这些微生物的患病率没有统计学上的显著变化。这表明需要更大规模和更具代表性的全国性数据来显示这些病原体的趋势。
